Mumbai-based healthtech startup, Truemeds, is making waves in the Indian pharmaceutical space with its innovative platform that helps consumers find alternative, cost-effective medicines by simply uploading their prescriptions. The company has announced plans to raise INR 375.2 crore (approximately $44 million) in a fresh funding round, with the investment being led by Accel India VII (Mauritius) Ltd. This funding round is a crucial milestone for Truemeds, helping it scale its operations and extend its impact in India’s rapidly growing digital healthcare market.
Read Also :- Policybazaar’s Parent PB Fintech Hits Record High, Market Value Nears $12 Billion
What is Truemeds?
Truemeds was founded by Akshat Nayyar and Kunal Wani with the mission of making healthcare more affordable and accessible to everyone. Through its platform, Truemeds allows users to upload their prescriptions and discover alternative, more affordable medicines without compromising on quality. This is particularly crucial in India, where the cost of healthcare can be a significant barrier for many, especially in underserved areas.
The platform not only offers alternative medicines but also provides a seamless experience, enabling users to easily compare prices from different suppliers and make informed purchasing decisions. Truemeds partners with various trusted pharmaceutical companies to offer a range of medications that are equivalent to the branded ones, often at a fraction of the cost. In a country where a large portion of the population struggles with the high cost of medications, this model has the potential to revolutionize how people access essential medicines.
Upcoming Funding Round and Strategic Plans
On February 17, 2025, Truemeds’ board passed a resolution to raise INR 375.2 crore by issuing up to 49,300 Series C compulsory convertible preference shares (Series C CCPS). These shares will be priced at INR 76,110.34 each, allowing the company to strengthen its financial position and accelerate its growth plans. The Series C round is a significant step in Truemeds’ journey, as it looks to expand its services across more regions in India and increase its user base.
Accel India VII (Mauritius) Ltd. will lead this funding round, further strengthening its portfolio in the Indian healthtech sector. Accel India, one of the most prominent venture capital firms, has been actively investing in innovative startups, and its involvement in Truemeds is a vote of confidence in the company’s ability to disrupt the healthcare space.
The fresh capital will be used for multiple purposes, including expanding the technology platform, enhancing product offerings, and expanding marketing efforts to reach a larger audience. With increased funding, Truemeds plans to extend its services to more cities and states, making its affordable healthcare solutions accessible to a broader demographic.
Truemeds’ Impact on the Indian Healthcare Ecosystem
The Indian healthcare system faces several challenges, including the high cost of medications and a lack of access to quality healthcare in rural areas. Truemeds’ model addresses these challenges directly, providing an effective solution that benefits both consumers and pharmaceutical companies. By helping people find affordable medicines, Truemeds can potentially save millions of families from financial strain while improving health outcomes across the nation.
In addition to making medications more affordable, Truemeds is also committed to promoting awareness and education on the importance of using the right medicines. By offering prescription-based solutions and engaging users in a transparent marketplace, Truemeds is not only facilitating access to cheaper alternatives but also fostering better health choices.
Looking Ahead
As the demand for digital healthcare solutions continues to rise in India, startups like Truemeds are poised to make a significant impact. With the support of investors like Accel India and its innovative approach to solving real-world problems, Truemeds is well-positioned for long-term success in the fast-evolving healthtech industry.
This fresh funding will enable Truemeds to further solidify its position as a leader in affordable healthcare and set the stage for its next phase of growth, benefiting millions of consumers across the country.
